The Institute of Cancer Policy (ICP) brings together the world’s largest global cancer research and policy faculty co-ordinated between King’s College London and London School of Hygiene & Tropical Medicine. The ICP works closely with UK Global Cancer Network and its global partners conducting policy evaluations, global cancer research and capacity building. The ICPs mission is to support the development of more affordable, equitable and high-quality cancer care and research across the world, particularly to support partners and countries to address some of the most challenging issues facing cancer control today, from conflict to economic sustainability.
The ICP has developed deep experience, expertise and evidence across complex health settings and system challenges for cancer control. We integrate advanced transdisciplinary research methods from epidemiology, economic and political sciences through to implementation science and health systems research. Community and patient involvement and understanding the broader social determinants of cancer is a central strategic pillar. The ICP has led over 15 Lancet and Lancet Oncology global cancer Commissions in the last decade as well as over 20 major global research programs.
The ICP has advised and conducted strategic insight research for national governments, the World Health Organisation, international research and economic bodies as well as humanitarian organisations. We also support a number of international cancer organisations to provide strategic global cancer intelligence in support of their work.
Active projects
- Lancet Oncology US Cancer Moonshot Commission. In a follow up to the first Moonshot commission the ICP is working with colleagues to examine national workforce challenges across Sub Saharan Africa and Latin America in the context of the Biden Moonshot program.
- Cancer in Crisis Lancet Oncology Commission. The ICP is co-leading this Commission with Global Institute of Psychosocial, Palliative & End-of-Life Care (GIPPEC) at Princess Margaret Hospital, Toronto to critical understand major issues in global cancer in light of multiple intersecting global challenges.
- Global Quality Indicators (QI) for Cancer Care for City Cancer Challenge. Currently in phase II (examining cancer quality indicators for cancer pathology, imaging, palliative care and financing) the ICP continues its groundbreaking work on QI in support of C/CAN’s wider mission.
- Commonwealth Lancet Oncology Commission. Initiated in 2024 the ICP is contributing to two workstreams of this new Commission.
- National cancer control planning for the UK. The ICP has co-led major strategic reviews and analysis into the UK’s national cancer control plans. Currently an in-depth examination of the strategic direction of UK cancer R&D is underway. Within this work the ICP have developed tools to inform cancer service planning https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00398-9/fulltext
- Cancer care in humanitarian settings (R4HC/R4HSSS). Following on from the recently published WHO-endorsed Manifesto following the joint ICP (King’s College London) / WHO UN NCD cancer in humanitarian settings meeting we are working with partners to develop high level operational engagement
- GACD funded multi-cancer early detection implementation science - Access Cancer Care India. Now in its 3rd year in collaboration with cancer leaders from India and WHO IARC this multi-site implementation science program continues its work to develop new models for early detection of high burden multiple cancers.
- Augmenting pelvic surgery training through virtual reality surgical simulation (VRSS) supported by Rosetrees Foundation/BASO. Our partnership with Zambian and Southern Methodist University (USA) colleagues to develop has now reached clinical development and validation stages.
- Supporting surgical oncology capacity development in Zambia. We are working to support Zambian colleagues in the development of a cancer surgical capacity plan, focused on pelvic (cervical cancer) and general surgery (breast cancer as well as broader research capacity plan.
- Supporting research prioritisation for cancer to inform national cancer control planning. We supported Zambian and Ugandan colleagues using a Delphi methodology to develop a key set of research priorities for prostate cancer care. https://bmjoncology.bmj.com/content/bmjonc/3/1/e000172.full.pdf
- ICP support several national and international Value based healthcare initiatives. As co-chair of the Health Economics in Radiation Oncology group within the European Society of Radiation Oncology, Ajay Aggarwal is one of the leaders of the value-based health care programs designed to support responsible and timely adoption of evidence based technologies. https://www.estro.org/Advocacy/ECF/Value-Based-HealthCare-(VBHC)
- Common Sense Oncology. As founding partners ICP continues to support core activities of CSO in particular on wider biopharmaceutical public policy. We currently have active projects on medicines regulatory policy in Brazil and European Union.
- Therapeutic geographies (TG) of cancer. Working with colleagues in the Middle East we are expanding our international work to look at how patients and care alter across national boundaries in response to insecurity, conflict and fragility. This work is closely tied to the world leading expertise in studying the TG of cancer patients across the UK.
- Building global resilience against Disease X into global cancer services & systems. Following the work of the COVID-19 and Cancer Global Taskforce co-led by the ICP and in collaboration with biosecurity experts through King’s Centre for Conflict & Health Research we are continuing our work to understand critical impact and mitigation strategies for cancer systems to future pandemics and building this intelligence into the work of the International Partnership for Resilience in Cancer Systems (IPaRCS).
- Trial evaluation of Artificial Intelligence for radiotherapy treatment. The ARCHERY study led by Ajay Aggarwal is the first prospective international trial across India, South Africa, Jordan and Malaysia evaluating the role of AI in radiotherapy with multiple partners include the Medical Research Council and MD Anderson Cancer Center.
- Quality Assessment and Assurance of Cancer Care – Ajay Aggarwal is the Clinical Director of the UK National Cancer Audit Collaborating Centre NATCAN oversee 10 national audits of cancer care, covering all public sector hospitals in the England and Wales NHS.
- Collabortive centre to WHO and provision of technical advice to key workstreams related to Noncommunicable diseases and cancer, including Global Cervical Cancer Screening and Treatment Guideline Development Group and Global Breast Cancer Initiative.
- Partner to the International Cancer Control Partnership and currently conducting a number of sub-analyses following the recent global review of NCCPs.
Media & Meetings
- ICP at the European Cancer Summit 2023 discussing conflict and cancer
- The UK’s failure to provide a coherent cancer plan. ICP commentary in Guardian
- ICP at the joint EMA / EORTIC Optimising Drug Development meeting in April 2024. How to better develop public policy for academic clinical trials
- ICP supported BMJ examination into issues with multi-cancer early detection test GrAiL
- ICP quoted in Men’s Health magazine article on early onset cancer
- Julie Torode, Ajay Aggarwal and Richard Sullivan will be presenting research and policy at the World Cancer Congress in Geneva in September 2024, covering global can cer surgery, cancer care in humanitarian settings, global cancer quality agenda, amongst many other topics.
Themes
Value, affordability and universal health coverage in global cancer
Since our leadership of the seminal Lancet Oncology Commission Delivering Affordable Cancer Care in High-Income Settings in 2011 we have developed a substantial global program on research into health system cancer economics, value of technologies (in particular medicines, radiotherapy and surgical devices), health technology assessment, value, prioritisation and consensus building e.g. Choosing Wisely India, and innovative financing for global cancer in some of the world’s most vulnerable populations e.g. refugees. Our work has been instrumental in understanding the macroeconomics of cancer (direct costs, as well as productivity losses due to premature mortality and morbidity) and their relationship to improving outcomes (value). We also work with WHO (Essential Medicines for Cancer Committee) and other organisations (e.g. ESTRO) to study the economic impact of technologies in specific contexts and link to different models of social protection, including in-depth ethnographic studies of affordability and cost of illness.
Cancer and palliative care in conflict
We are world leaders in research in the development and delivery of cancer and palliative care in conflict ecosystems through our work with the R4HC-MENA and R4HSSS. Over the last five years, we having been developing capacity and capability for cancer research germane to conflict-humanitarian settings including novel financing with partners in Turkey, Jordan, Pakistan, Palestine and Lebanon. In addition, formative work has been undertaken to understand the unique system issues for delivering cancer care to refugees. Lastly, we have a number of ongoing clinical intervention studies in conflict settings, for example, integrated palliative outcome scale. We are currently supporting WHO on cancer intelligence for the Ukrainian conflict (see Activity tab).
COVID-19 and Cancer Global Taskforce
The Covid-19 and Cancer Taskforce is a global group of cancer leaders spanning the disciplines of cancer across the care continuum from prevention, early detection, treatment and palliative care, to representatives of cancer centre networks and advocacy groups. The taskforce, led by GOG, has been studying the immediate impacts on cancer patients, services, and healthcare workers in high and low & middle income settings as well as treatment decision making and patient/doctor interactions. We also directly address risks for longer-term impacts on cancer outcomes, inequalities, cancer research capacity and affordability of care by developing new approaches to build resilient cancer services with readiness to respond to pandemics, especially in low- and middle-income countries whose cancer services are especially vulnerable in the face of this unprecedented public health challenge.
Global cancer research systems
GOG works with partners around the world to support the development of research capacity and capability, an essential part of national cancer control programs and delivering more affordable and better patient outcomes. We have a long-standing partnership with Tata Memorial Centre and the National Cancer Grid of India to support research capacity through the CReDO (International Collaboration for Research methods Development in Oncology) program, as well as capacity-building programs in the Middle East and Sub Saharan Africa, particularly Zambia and Ghana. GOG also has a very active research program using research intelligence tools (scientometrics) to analyse cancer research systems. Our cancer research mapping has been utilised by a wide range of Lancet Oncology and World Bank DCP3 Commissions to inform national and global policy.
Innovative technologies for global cancer
GOG has a wide range of clinical studies and programs ongoing including artificial intelligence (AI) based radiotherapy treatment planning and the development of virtual reality surgical simulation for cancer surgery with LMIC partners across the globe. The Group also has significant expertise and ongoing projects in low-cost diagnostic technologies such as Cyto-sponge for Barret’s oesophagus and a range of technologies for cervical screening. This work is underpinned by programs of public policy and health systems analysis to understand the implementation and impact of cancer technologies once they enter cancer systems. GOG particularly works with WHO IARC (International Agency for Research on Cancer) with its technology implementation science programs. GOG has created collaborations with leaders in the field of technology development such as Southern Methodist University and MD Anderson with major partners across over a dozen LMIC countries.
Global cancer services and systems
GOG studies how different models of health (cancer) system design impact equity in access, travel burden and patient outcomes in collaboration with our partners at LSHTM. We have supported many countries in examining their cancer care systems as part of national cancer control planning. In addition, we have major programs in cancer services and systems especially for urological and bowel cancers , as well as work on cancer surgical systems and new models of service design to deliver radiotherapy. Our current work focuses on how optimising the structure and function of health services improves cancer outcomes in a range of different LMIC settings using patient focused measures. Our work in health (cancer) services and systems is aligned with broader studies around the political economy of cancer care and evolving nature of cross national border cancer care. GOG has supported systems research for both adult and childhood cancers. In the latter, we work closely with major organisations such as SIOP and the World Health Organisation.
Lived experiences and patient perspectives in global cancer
The growing incidence of cancer that low- and middle-income countries face is raising social, cultural, political, ethical, and economic challenges of global cancer that require research beyond the traditional biomedical-clinical nexus. GOG pursues social science studies led by Dr Carlo Caduff [https://www.kcl.ac.uk/people/carlo-caduff] committed to qualitative research methods that foreground the narratives and perspectives of a wide range of stakeholders (i.e. patients, family members, medical practitioners at all levels and from many systems of medicine). Our aim is to give voice to the lived experiences, motivations and constraints of all who are touched by cancer and involved in cancer care. This approach humanizes and adds richness to our understanding of cancer in heterogeneous and complex settings across the world. As part of this work stream, we have also contributed to building social science research capacity in the global south.
Publications
Palliative Care in Turkey: Insights from Experts through Key Informant Interviews
Ahmed, F., Kutluk, T., Yurduşen, S., Şengelen, M., Aydın, B., Kirazli, M., Aydın, S., Sullivan, R. & Harding, R., 18 Sept 2024, (E-pub ahead of print) In: Journal of Cancer Policy. 42, p. 100506 100506.Research output: Contribution to journal › Article › peer-review
Breast Cancer in Women in Gaza: A Review of Clinical Characteristics and Short-Term Survival
Alwaheidi, S., Sullivan, R. & Davies, E. A., 2024, In: JCO global oncology. 10, e2300170.Research output: Contribution to journal › Article › peer-review
National Palliative Care Strategy in a Conflict Affected Country: A Jordanian Demonstration Project
Shamieh, O., Alarjeh, G., Hammad, R., Payne, S., Harding, R., Sullivan, R. & Mansour, A., 28 Dec 2023, (E-pub ahead of print) In: Journal of pain and symptom management.Research output: Contribution to journal › Article › peer-review
Stress, resilience, and moral distress among health care providers in oncology during the COVID-19 pandemic
Alrjoub, W., Alarjeh, G., Ammar, K., Shamieh, A., Harding, R., Booth, C., Sullivan, R., Al-Ruzzieh, M., Mansour, A. & Shamieh, O., 19 Dec 2023, In: Frontiers in Public Health. 11, p. 1288483Research output: Contribution to journal › Article › peer-review
Toward an integrated approach for mental health and psychosocial support and peacebuilding in North-East Nigeria: programme description and preliminary outcomes from ‘Counselling on Wheels’
Paphitis, S., Akilu, F., Chilambo, N., Iruayenama, A., Samaroo, X., Mustapha, A., Goldsmith, K., Ismail, O., Slovak, P., Ikpe, E., Smith, P., Patel, P., Sullivan, R., Abas, M. A. & Olonisakin, F., 12 Oct 2023, In: BJPsych Open. 9, 6, e190.Research output: Contribution to journal › Article › peer-review
Revitalising cancer trials post-pandemic: time for reform
Morton, C., Sullivan, R., Sarker, D., Posner, J. & Spicer, J., 12 Apr 2023, In: British journal of cancer. 128, 8, p. 1409-1414 6 p.Research output: Contribution to journal › Article › peer-review
Providing person-centered palliative care in conflict-affected populations in the Middle East: What matters to patients with advanced cancer and families including refugees?
Guo, P., Alajarmeh, S., Alarjeh, G., Alrjoub, W., Al-Essa, A., Abusalem, L., Giusti, A., Mansour, A. H., Sullivan, R., Shamieh, O. & Harding, R., 27 Mar 2023, In: Frontiers in oncology. 13, 1097471.Research output: Contribution to journal › Article › peer-review
The challenges of international collaboration in conflict and health research: experience from the Research for Health in Conflict-Middle East and North Africa (R4HC-MENA) partnership
Bricknell, M., Lin, C.-Y., Sullivan, R., Meagher, K., Patel, P., El Achi, N., Kutluk, T., Harding, R., Kienzler, H., Giacaman, R., Mukherji, D. & Shamieh, O., Dec 2023, In: Conflict and health. 17, 1, 29.Research output: Contribution to journal › Article › peer-review
Redefining cancer research priorities in low- and middle-income countries in the post-COVID-19 global context: a modified Delphi consensus process
Fox, L., Santaolalla, A., Handford, J., Sullivan, R., Torode, J., Vanderpuye , V., Pramesh, C. S., Mula-Hussain, L., Alwaheidi, S., Makaroff, L., Kaur, R., Mackay, C., Mukherji, D. & Van Hemelrijck, M., 10 Aug 2023, In: JCO Global Oncology. p. 1-16 16 p.Research output: Contribution to journal › Article › peer-review
Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward
Jenei, K., Aziz, Z., Booth, C., Cappello, B., Ceppi, F., de Vries, E. G. E., Fojo, A., Gyawali, B., Ilbawi, A., Lombe, D., Sengar, M., Sullivan, R., Trapani, D., Huttner, B. D. & Moja, L., 29 Sept 2022, (E-pub ahead of print) In: The Lancet. Global health. S2214-109X(22)00376-X.Research output: Contribution to journal › Article › peer-review
Global colorectal cancer research, 2007-2021: Outputs and funding
Begum, M., Lewison, G., Wang, X., Dunne, P. D., Maughan, T., Sullivan, R. & Lawler, M., 1 Feb 2023, In: International Journal of Cancer. 152, 3, p. 470-479 10 p.Research output: Contribution to journal › Article › peer-review
Informal Providers—Ground Realities in South Asian Association for Regional Cooperation Nations: Toward Better Cancer Primary Care: A Narrative Review
Nayak, P. R., Oswal, K., Pramesh, C., Ranganathan, P., Sullivan, R., Caduff, C., Advani, S., Kataria, I., Kalkonde, Y., Mohan, P., Jain, Y. & Purushotham, A., 31 Oct 2022, (E-pub ahead of print) In: JCO global oncology.Research output: Contribution to journal › Review article › peer-review
Cancer research across Africa: a comparative bibliometric analysis
Sullivan, R., 14 Sept 2022, (Accepted/In press) In: The Lancet. Global health. 26 p.Research output: Contribution to journal › Article › peer-review
Palliative Care in 2020 & Beyond Workshop: an expert symposium to develop palliative care advocacy in Turkey
Ahmed, F., Kutluk, T., Kirazli, M., Yurduşen, S., Cemaloğlu, M., Boufkhed, S., Şengelen, M., Aydın, B., Sullivan, R. & Harding, R., Dec 2022, In: Journal of Cancer Policy. 34, 100361.Research output: Contribution to journal › Article › peer-review
System-Level Capacity of High-Dose Rate (HDR) Brachytherapy for Management of Cervical Cancer in an Upper-Middle Income Country: A Case Study From Brazil
Gouveia, A. G., Viani, G. A., Bratti, V. F., Pavoni, J. F., Sullivan, R., Rosa, A. A., Booth, C. M., Aggarwal, A., Hanna, T. P. & Moraes, F. Y., 1 Nov 2022, In: International Journal of Radiation Oncology Biology Physics. 114, 3, p. 545-553 9 p.Research output: Contribution to journal › Article › peer-review
Participation of Lower and Upper Middle-Income Countries in Clinical Trials Led by High-Income Countries
Rubagumya, F., Hopman, W. M., Gyawali, B., Mukherji, D., Hammad, N., Pramesh, C. S., Zubaryev, M., Eniu, A., Tsunoda, A. T., Kutluk, T., Aggarwal, A., Sullivan, R. & Booth, C. M., 1 Aug 2022, In: JAMA Network open. 5, 8, p. e2227252Research output: Contribution to journal › Article › peer-review
Health service planning to assess the expected impact of centralising specialist cancer services on travel times, equity, and outcomes: a national population-based modelling study
Aggarwal, A., Han, L., van der Geest, S., Lewis, D., Lievens, Y., Borras, J., Jayne, D., Sullivan, R., Varkevisser, M. & van der Meulen, J., Sept 2022, In: The Lancet Oncology. 23, 9, p. 1211-1220 10 p.Research output: Contribution to journal › Article › peer-review
Editorial: The effects of COVID-19 on cancer research methods & strategies
Fox, L., Sullivan, R., Mukherji, D. & Van Hemelrijck, M., 10 Aug 2022, In: Frontiers in Public Health. 10, 988736.Research output: Contribution to journal › Editorial › peer-review
Cancer Medicines: What Is Essential and Affordable in India?
Sengar, M., Fundytus, A., Hopman, W., Pramesh, C. S., Radhakrishnan, V., Ganesan, P., Mathew, A., Lombe, D., Jalink, M., Gyawali, B., Trapani, D., Roitberg, F., De Vries, E. G. E., Moja, L., Ilbawi, A., Sullivan, R. & Booth, C. M., 1 Jul 2022, In: JCO global oncology. 8, p. e2200060Research output: Contribution to journal › Article › peer-review
The health of internally displaced people in Syria: are current systems fit for purpose?
Ekzayez, A., Abbara, A., Rayes, D., Jabbour, S., Marzouk, M., Alnahhas, H., Basha, S., Katurji, Z., Sullivan, R. & M Fouad, M. F., 21 Jul 2022, (E-pub ahead of print) In: Journal of Migration and Health. 6, 100126.Research output: Contribution to journal › Article › peer-review
Radiotherapy in conflict: lessons from Ukraine
Price, P., Sullivan, R., Zubarev, M. & Zelinskyi, R., Jul 2022, In: The Lancet Oncology. 23, 7, p. 845-847 3 p.Research output: Contribution to journal › Comment/debate › peer-review
Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey
Denburg, A. E., Fundytus, A., Khan, M. S., Howard, S. C., Antillon-Klussmann, F., Sengar, M., Lombe, D., Hopman, W., Jalink, M., Gyawali, B., Trapani, D., Roitberg, F., De Vries, E. G. E., Moja, L., Ilbawi, A., Sullivan, R. & Booth, C. M., 1 Jun 2022, In: JCO global oncology. 8, p. e2200034Research output: Contribution to journal › Article › peer-review
The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence
Carle, C., Hughes, S., Freeman, V., Campbell, D., Egger, S., Caruana, M., Hui, H., Yap, S., Deandrea, S., Onyeka, T. C., IJzerman, M. J., Ginsburg, O., Bray, F., Sullivan, R., Aggarwal, A., Peacock, S. J., Chan, K. K. W., Hanna, T. P., Soerjomataram, I. & O'Connell, D. L. & 2 others, Canfell, K. & Steinberg, J., Sept 2022, In: Journal of Cancer Policy. 33, 100338.Research output: Contribution to journal › Review article › peer-review
Are patients with cancer at higher risk of COVID-19-related death? A systematic review and critical appraisal of the early evidence
Freeman, V., Hughes, S., Carle, C., Campbell, D., Egger, S., Hui, H., Yap, S., Deandrea, S., Caruana, M., Onyeka, T. C., IJzerman, M. J., Ginsburg, O., Bray, F., Sullivan, R., Aggarwal, A., Peacock, S. J., Chan, K. K. W., Hanna, T. P., Soerjomataram, I. & O'Connell, D. L. & 2 others, Steinberg, J. & Canfell, K., Sept 2022, In: Journal of Cancer Policy. 33, 100340.Research output: Contribution to journal › Review article › peer-review
Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer
Henderson, R. H., French, D., McFerran, E., Adams, R., Wasan, H., Glynne-Jones, R., Fisher, D., Richman, S., Dunne, P. D., Wilde, L., Maughan, T. S., Sullivan, R. & Lawler, M., Sept 2022, In: Journal of Cancer Policy. 33, 100342.Research output: Contribution to journal › Article › peer-review
Cancer in sub-Saharan Africa: a Lancet Oncology Commission
Ngwa, W., Addai, B. W., Adewole, I., Ainsworth, V., Alaro, J., Alatise, O. I., Ali, Z., Anderson, B. O., Anorlu, R., Avery, S., Barango, P., Bih, N., Booth, C. M., Brawley, O. W., Dangou, J. M., Denny, L., Dent, J., Elmore, S. N. C., Elzawawy, A. & Gashumba, D. & 33 others, Geel, J., Graef, K., Gupta, S., Gueye, S. M., Hammad, N., Hessissen, L., Ilbawi, A. M., Kambugu, J., Kozlakidis, Z., Manga, S., Maree, L., Mohammed, S. I., Msadabwe, S., Mutebi, M., Nakaganda, A., Ndlovu, N., Ndoh, K., Ndumbalo, J., Ngoma, M., Ngoma, T., Ntizimira, C., Rebbeck, T. R., Renner, L., Romanoff, A., Rubagumya, F., Sayed, S., Sud, S., Simonds, H., Sullivan, R., Swanson, W., Vanderpuye, V., Wiafe, B. & Kerr, D., Jun 2022, In: The Lancet Oncology. 23, 6, p. e251-e312Research output: Contribution to journal › Review article › peer-review
How Should Access to Military Health Care Facilities Be Controlled in Conflict?
Bricknell, M., Sullivan, R., Whetham, D. & Mahoney, P., 2 Jun 2022, In: AMA Journal of Ethics. 24, 6, p. E472-E477 5 p.Research output: Contribution to journal › Article › peer-review
Adaptation of Intercultural Sensitivity Scale for Turkish medical students
Bahar-Özvarış, Ş., Güçiz-Doğan, B., Konşuk-Ünlü, H., Şanver, T. M., Susuz, Ç. & Sullivan, R., May 2022, In: International Journal of Intercultural Relations. 88, p. 163-176 14 p.Research output: Contribution to journal › Article › peer-review
Conflict in Ukraine undermines an already challenged health system
Roborgh, S., Coutts, A. P., Chellew, P., Novykov, V. & Sullivan, R., 9 Apr 2022, In: The Lancet. 399, 10333, p. 1365-1367 3 p.Research output: Contribution to journal › Comment/debate › peer-review
Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity
Connor Wells, J., Fundytus, A., Sharma, S., Hopman, W. M., Del Paggio, J. C., Gyawali, B., Mukherji, D., Hammad, N., Pramesh, C. S., Aggarwal, A., Sullivan, R. & Booth, C. M., Apr 2022, In: Current Oncology. 29, 4, p. 2530-2538 9 p.Research output: Contribution to journal › Article › peer-review
Priorities for cancer research in low- and middle-income countries: a global perspective
Pramesh, C. S., Badwe, R. A., Bhoo-Pathy, N., Booth, C. M., Chinnaswamy, G., Dare, A. J., de Andrade, V. P., Hunter, D. J., Gopal, S., Gospodarowicz, M., Gunasekera, S., Ilbawi, A., Kapambwe, S., Kingham, P., Kutluk, T., Lamichhane, N., Mutebi, M., Orem, J., Parham, G. & Ranganathan, P. & 8 others, Sengar, M., Sullivan, R., Swaminathan, S., Tannock, I. F., Tomar, V., Vanderpuye, V., Varghese, C. & Weiderpass, E., Apr 2022, In: Nature Medicine. 28, 4, p. 649-657 9 p.Research output: Contribution to journal › Article › peer-review
Primary care and cancer: an analysis of the impact and inequalities of the COVID-19 pandemic on patient pathways
Watt, T., Sullivan, R. & Aggarwal, A., 24 Mar 2022, In: BMJ Open. 12, 3, p. e059374 e059374.Research output: Contribution to journal › Article › peer-review
Prioritising locations for radiotherapy equipment in Brazil: a cross-sectional, population-based study and development of a LINAC shortage index
Viani, G. A., Gouveia, A. G., Bratti, V. F., Pavoni, J. F., Sullivan, R., Hopman, W. M., Booth, C. M., Aggarwal, A., Hanna, T. P. & Moraes, F. Y., Apr 2022, In: The Lancet Oncology. 23, 4, p. 531-539 9 p.Research output: Contribution to journal › Article › peer-review
Cancer research collaboration between the UK and the USA: reflections on the 2021 G20 Summit announcement
Sullivan, R., Lewison, G., Torode, J., Kingham, P. T., Brennan, M., Shulman, L. N., Lawler, M., Aggarwal, A. & Gralow, J., Apr 2022, In: The Lancet Oncology. 23, 4, p. 460-462 3 p.Research output: Contribution to journal › Comment/debate › peer-review
Is Clinical Research Serving the Needs of the Global Cancer Burden? An Analysis of Contemporary Global Radiation Therapy Randomized Controlled Trials
Dodkins, J., Hopman, W. M., Wells, J. C., Lievens, Y., Malik, R. A., Pramesh, C. S., Gyawali, B., Hammad, N., Mukherji, D., Sullivan, R., Parkes, J., Booth, C. M. & Aggarwal, A., 1 Jul 2022, In: International Journal of Radiation Oncology Biology Physics. 113, 3, p. 500-508 9 p.Research output: Contribution to journal › Article › peer-review
COVID-19 vaccination in patients with cancer, a rapid review
on behalf of the Cancer and COVID-19 Global Taskforce, 2022, In: ecancermedicalscience. 16, 1355.Research output: Contribution to journal › Review article › peer-review
COVID-19 and Cancer Global Modelling Consortium (CCGMC): A global reference to inform national recovery strategies
Soerjomataram, I., Bray, F., Lansdorp-Vogelaar, I., Ginsburg, O., Rahal, R., Sullivan, R. & Canfell, K., 1 Jun 2022, In: Journal of Cancer Policy. 32, 100328.Research output: Contribution to journal › Article › peer-review
What Really Matters for Cancer Care – Health Systems Strengthening or Technological Innovation?
Aggarwal, A., Lievens, Y., Sullivan, R. & Nolte, E., Jul 2022, In: Clinical Oncology. 34, 7, p. 430-435 6 p.Research output: Contribution to journal › Editorial › peer-review
Cancer among syrian refugees living in Konya Province, Turkey
Kutluk, T., Koç, M., Öner, İ., Babalıoğlu, İ., Kirazlı, M., Aydın, S., Ahmed, F., Köksal, Y., Tokgöz, H., Duran, M. & Sullivan, R., 31 Jan 2022, (E-pub ahead of print) In: Conflict and health. 16, 1, 3.Research output: Contribution to journal › Article › peer-review
Building Resilient Health Systems Intelligence: Adapting Indicators of Compromise for the Cyber-Bionexus
Bowsher, G., Bernard, R. & Sullivan, R., 1 Nov 2021, In: Health security. 19, 6, p. 625-632 8 p.Research output: Contribution to journal › Article › peer-review
Progress in palliative care for cancer in Turkey: A review of the literature
Kutluk, T., Ahmed, F., Cemaloğlu, M., Aydın, B., Şengelen, M., Kirazli, M., Yurduşen, S., Sullivan, R. & Harding, R., 2021, In: ecancermedicalscience. 15, 1321.Research output: Contribution to journal › Article › peer-review
Understanding the structure of a country's health service providers for defence health engagement
Bricknell, M., Hinrichs-Krapels, S., Ismail, S. & Sullivan, R., 1 Dec 2021, In: BMJ Military Health. 167, 6, p. 454-456 3 p.Research output: Contribution to journal › Article › peer-review
Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England
Fox, L., Monroy Iglesias, M., Aggarwal, A., Haire, K., Purushotham, A., Spicer, J., Papa, S., Rigg, A., Dolly, S., Sullivan, R. & Van Hemelrijck, M., 8 Dec 2021, (E-pub ahead of print) In: Journal of Cancer Policy.Research output: Contribution to journal › Article › peer-review
The Lancet Commission on diagnostics: transforming access to diagnostics
Fleming, K. A., Horton, S., Wilson, M. L., Atun, R., DeStigter, K., Flanigan, J., Sayed, S., Adam, P., Aguilar, B., Andronikou, S., Boehme, C., Cherniak, W., Cheung, A. N., Dahn, B., Donoso-Bach, L., Douglas, T., Garcia, P., Hussain, S., Iyer, H. S. & Kohli, M. & 12 others, Labrique, A. B., Looi, L. M., Meara, J. G., Nkengasong, J., Pai, M., Pool, K. L., Ramaiya, K., Schroeder, L., Shah, D., Sullivan, R., Tan, B. S. & Walia, K., 1 Oct 2021, In: The Lancet. 398, 10315, p. 1997-2050 54 p.Research output: Contribution to journal › Article › peer-review
Global cancer research in the post-pandemic world
COVID-19 and Cancer Task Force, Dec 2021, In: The Lancet Oncology. 22, 12, p. 1652-1654 3 p.Research output: Contribution to journal › Comment/debate › peer-review
Supporting more affordable and equitable cancer care and research in Lower and Middle Income Countries: Ecancer’s commitment
Sullivan, R., Cazap, E. & Burke, D., 2021, In: ecancermedicalscience. 15, ed116.Research output: Contribution to journal › Editorial › peer-review
Cancer in the older Indian population: Understanding the current context in an emerging economy
Nethan, S., Cherian, M., Brain, E., Ganguli, A., Tullu, F., Musolino, N., Hariprasad, R., Sullivan, R. & Mehrotra, R., 11 Nov 2021, (E-pub ahead of print) In: Journal of Geriatric Oncology.Research output: Contribution to journal › Article › peer-review
Factors affecting COVID-19 outcomes in cancer patients from Guy's Cancer Center and King's College Hospital.
Palmer, K., Sylva, R., Russell, B., Moss, C., Shah, V., Ko, T. K., George, G., Kordasti, S., Crawley, D., Wylie, H., Cahill, F., Haire, A., Zaki, K., Sita-Lumsden, A., Josephs, D., Enting, D., Swampillai, A., Sawyer, E., Lei, M. & D'Souza, A. & 8 others, Gomberg, S., Fields, P., Wrench, D., Sullivan, R., Rigg, A., Kulasekararaj, A., Van Hemelrijck, M. & Dolly, S., Mar 2020, In: Clinical Cancer Research. 27, 6Research output: Contribution to journal › Meeting Abstract › peer-review
Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study
Meyers, D. E., Meyers, B. S., Chisamore, T. M., Wright, K., Gyawali, B., Prasad, V., Sullivan, R. & Booth, C. M., 15 Jan 2022, In: Cancer. 128, 2, p. 311-316 6 p.Research output: Contribution to journal › Article › peer-review
Impact of the COVID-19 pandemic on cancer researchers in 2020: a qualitative study of events to inform mitigation strategies
Fox, L., Beyer, K., Rammant, E., Morcom, E., Van Hemelrijck, M., Sullivan, R., Vanderpuye, V., Lombe, D., Tsunoda, A. T., Kutluk, T., Bhoo-Pathy, N., Pramesh, S. C., Yusuf, A., Booth, C. M., Shamieh, O., Siesling, S. & Mukherji, D., 24 Nov 2021, In: Frontiers in Public Health.Research output: Contribution to journal › Article › peer-review
Awards
UKRI Global Challenge Research Fund grant (£7M) to build research capacity and capability across Middle East and North Africa
NIHR grant (£4M) to strengthen systems and services in NW and NE Syria
Welcome Trust and Medical Research grants (£1M+) to develop low-cost virtual reality to support surgery capacity in LMIC
Global Alliance for Chronic Disease grant (£2M) to support implementation of affordable, equitable and integrated multi-cancer early detection package in India
Welcome Trust (£1M+) Artificial Intelligence to Automate Radiotherapy to Treat Advanced Cancers
Welcome Trust (£1M+) Grid oncology: remaking cancer care in India
ISSF (£1M) African Prostate Cancer Disparities in Outcomes
STFC (£1M) Cloud-Based Electronic Platforms in Support of Complex Radiotherapy Planning and Research Capacity
Activities
eCancer
GOG partners closely with eCancer, a free to publish and free to access multi-media platform, that is both a publisher and a developer of free educational content with a specific focus on global cancer in LMIC. Through eCancer we create free content including briefings on topical global cancer issues, new educational content, and intelligence resources for example on COVID-19 and Cancer. We also work with eCancer to bring global webinars on ‘hot topics’ and virtual conference proceedings from all the major global meetings including eCancer patient and Spanish portals for Latin American faculty.
Journal of Cancer Policy
The Journal of Cancer Policy is GOG’s own brand cancer policy journal. Launched in 2015 it has provided a platform for a wide range of research, commentaries, and major series reflecting the plurality and depth of global oncology. The Journal of Cancer Policy is an international journal that publishes research and reviews on global cancer policy. The journal encompasses all aspects of cancer policy from prevention and public health through all modalities of control and cure, palliative care, and survivorship. It provides a platform for policy research and discussion around the world from New Zealand to Niger.
London Global Cancer Week
As founding members of UK Global Cancer Research Network the Global Oncology Group and Institute of Cancer Policy are hosting two major sessions at LGCW from 14 to 19 November. On 15th November join us for an examination of cancer care – the balance of costs with the Royal Society of Medicine and on 17th November we will co-host with The Lancet an update on the Women and Cancer Commission
Lancet Commission on Diagnostics
The ICP joined an international group of experts to examine the state of Global Diagnostics and provide recommendations to improve the support of this critical area as part of Universal Health Coverage.
Conferences
Faculty from GOG will be involved in the following global cancer meetings. Come and join us!
AORTIC
The Global Oncology Group through the Institute of Cancer Policy is an active member of the African Organization for Research and Training In Cancer (AORTIC). In addition to GOG research capacity building projects across SSA from virtual reality surgical simulation to palliative care, the GOG believes in investing in African partners, contributing to their organizational financial models towards operational independence and sustainability of their own efforts to build research and policy capacity and capability.
Supporting Ukrainian Cancer Care
The Russian invasion of Ukraine has created a profound cancer (and NCD) humanitarian crisis. The Global Oncology Group is providing critical health intelligence for cancer and palliative care during this crisis through the creation of a health security intelligence group. This group brings together global cancer experience from the Global Oncology Group at the Institute of Cancer Policy and the Cicely Saunders Institute for Palliative Care. Professor Richard Sullivan is a member of the WHO Cancer Emergency Committee and co-chairs the European Cancer Organisation and American Society of Clinical Oncology Ukrainian network. The King’s group is also assisting with estimates and analysis on the pathways Ukrainian cancer patients are taking through Europe and the capacity/capability of cancer centres in host countries to manage what has been a rapidly increasing additional burden. Much of the insight we are bringing to this crisis has been drawn from our work with colleagues in Lebanon, Turkey, Jordan and Palestine over the last five years on the Research for Health in Conflict program looking at cancer care within the Syrian conflict and during the war in Afghanistan.
Building performance metrics for the City Cancer Challenge Foundation
With most of the urban growth expected to take place in Low- and Middle-Income Countries (LMICs), cities are uniquely positioned to build resilient cancer health systems from the ground up. The City Cancer Challenge Foundation model leverages the entrepreneurship and leadership of cities to co-create new ways of working to drive equitable access to quality cancer management services. Institute of Cancer Policy, Global Oncology Group is proud to be working with the Foundation to develop an evidenced-based, three-tiered set of long-term performance indicators which, when implemented, support cancer centres in establishing a critical path of data collection to underpin monitoring and evaluation of cancer treatment and palliative care in a longitudinal manner and a key step towards incremental improvement of services and sustainability. This work will be implemented with the support of expert discussions groups drawn for the Global Oncology Group. We anticipate delivery of phase 1 reports to the City Cancer Challenge Foundation in May, with follow up work to consolidate recommendations for cancer centres in LMICs by October 2022.
News
Global analysis of cancer research papers reveals consistent sex imbalance
New research analysing female authorship of cancer research papers over a 10 year period has found a consistent sex imbalance, despite a modest increase in...
Multi-billion productivity cost of head and neck cancer revealed
New research describes a $5.6 billion (USD) loss of productivity from head and neck cancer in India during 2022, emblematic of its rising economic impact...
King's helps build cancer partnerships across Sub-Saharan Africa
The Global Oncology Group played a major role at this year’s African Organisation for Research and Training in Cancer (AORTIC) in promoting partnerships and...
Leading cancer doctors raise the alarm about “serious missteps” on cancer policy
The loss of a dedicated National Cancer Control Plan in England and Wales has been a “major misstep” at a time when the NHS is facing massive workforce...
2023 Surgery Commission offers solutions to improve cancer surgery outcomes
King’s academics have collaborated with researchers, doctors and surgeons to make eight recommendations to help improve cancer surgery outcomes across the...
ICP Board
- Mark Lawler, Belfast, Northern Ireland
- Omar Shamieh, King Hussein Cancer Centre, Jordan
- Tezer Kutluk, Hacettepe University Hospital, Turkey
- Enrique Soto Pérez de Celis, University of Colorado Cancer Centre, USA
- Karla Ungar, National Cancer Institute, Mexico
- Ishu Kataria, RTI, USA and India
- Chris Booth, Queen’s University, Canada
- Kathleen Schmeler, MD Anderson, USA
- Peter Kingham, Memorial Sloan Kettering, USA
- CS Pramesh, Tata Memorial Centre, Mumbai, India
- Gevorg Tamamyan, Yerevan State Medical University, Armenia
- Miriam Mutebi, Aga Khan University, Nairobi, Kenya
- Partha Basu, WHO International Agency for Research on Cancer
- Nirmala Bhoo-Pathy, University of Malaysia
- Yolande Lievens, University of Ghent
Themes
Value, affordability and universal health coverage in global cancer
Since our leadership of the seminal Lancet Oncology Commission Delivering Affordable Cancer Care in High-Income Settings in 2011 we have developed a substantial global program on research into health system cancer economics, value of technologies (in particular medicines, radiotherapy and surgical devices), health technology assessment, value, prioritisation and consensus building e.g. Choosing Wisely India, and innovative financing for global cancer in some of the world’s most vulnerable populations e.g. refugees. Our work has been instrumental in understanding the macroeconomics of cancer (direct costs, as well as productivity losses due to premature mortality and morbidity) and their relationship to improving outcomes (value). We also work with WHO (Essential Medicines for Cancer Committee) and other organisations (e.g. ESTRO) to study the economic impact of technologies in specific contexts and link to different models of social protection, including in-depth ethnographic studies of affordability and cost of illness.
Cancer and palliative care in conflict
We are world leaders in research in the development and delivery of cancer and palliative care in conflict ecosystems through our work with the R4HC-MENA and R4HSSS. Over the last five years, we having been developing capacity and capability for cancer research germane to conflict-humanitarian settings including novel financing with partners in Turkey, Jordan, Pakistan, Palestine and Lebanon. In addition, formative work has been undertaken to understand the unique system issues for delivering cancer care to refugees. Lastly, we have a number of ongoing clinical intervention studies in conflict settings, for example, integrated palliative outcome scale. We are currently supporting WHO on cancer intelligence for the Ukrainian conflict (see Activity tab).
COVID-19 and Cancer Global Taskforce
The Covid-19 and Cancer Taskforce is a global group of cancer leaders spanning the disciplines of cancer across the care continuum from prevention, early detection, treatment and palliative care, to representatives of cancer centre networks and advocacy groups. The taskforce, led by GOG, has been studying the immediate impacts on cancer patients, services, and healthcare workers in high and low & middle income settings as well as treatment decision making and patient/doctor interactions. We also directly address risks for longer-term impacts on cancer outcomes, inequalities, cancer research capacity and affordability of care by developing new approaches to build resilient cancer services with readiness to respond to pandemics, especially in low- and middle-income countries whose cancer services are especially vulnerable in the face of this unprecedented public health challenge.
Global cancer research systems
GOG works with partners around the world to support the development of research capacity and capability, an essential part of national cancer control programs and delivering more affordable and better patient outcomes. We have a long-standing partnership with Tata Memorial Centre and the National Cancer Grid of India to support research capacity through the CReDO (International Collaboration for Research methods Development in Oncology) program, as well as capacity-building programs in the Middle East and Sub Saharan Africa, particularly Zambia and Ghana. GOG also has a very active research program using research intelligence tools (scientometrics) to analyse cancer research systems. Our cancer research mapping has been utilised by a wide range of Lancet Oncology and World Bank DCP3 Commissions to inform national and global policy.
Innovative technologies for global cancer
GOG has a wide range of clinical studies and programs ongoing including artificial intelligence (AI) based radiotherapy treatment planning and the development of virtual reality surgical simulation for cancer surgery with LMIC partners across the globe. The Group also has significant expertise and ongoing projects in low-cost diagnostic technologies such as Cyto-sponge for Barret’s oesophagus and a range of technologies for cervical screening. This work is underpinned by programs of public policy and health systems analysis to understand the implementation and impact of cancer technologies once they enter cancer systems. GOG particularly works with WHO IARC (International Agency for Research on Cancer) with its technology implementation science programs. GOG has created collaborations with leaders in the field of technology development such as Southern Methodist University and MD Anderson with major partners across over a dozen LMIC countries.
Global cancer services and systems
GOG studies how different models of health (cancer) system design impact equity in access, travel burden and patient outcomes in collaboration with our partners at LSHTM. We have supported many countries in examining their cancer care systems as part of national cancer control planning. In addition, we have major programs in cancer services and systems especially for urological and bowel cancers , as well as work on cancer surgical systems and new models of service design to deliver radiotherapy. Our current work focuses on how optimising the structure and function of health services improves cancer outcomes in a range of different LMIC settings using patient focused measures. Our work in health (cancer) services and systems is aligned with broader studies around the political economy of cancer care and evolving nature of cross national border cancer care. GOG has supported systems research for both adult and childhood cancers. In the latter, we work closely with major organisations such as SIOP and the World Health Organisation.
Lived experiences and patient perspectives in global cancer
The growing incidence of cancer that low- and middle-income countries face is raising social, cultural, political, ethical, and economic challenges of global cancer that require research beyond the traditional biomedical-clinical nexus. GOG pursues social science studies led by Dr Carlo Caduff [https://www.kcl.ac.uk/people/carlo-caduff] committed to qualitative research methods that foreground the narratives and perspectives of a wide range of stakeholders (i.e. patients, family members, medical practitioners at all levels and from many systems of medicine). Our aim is to give voice to the lived experiences, motivations and constraints of all who are touched by cancer and involved in cancer care. This approach humanizes and adds richness to our understanding of cancer in heterogeneous and complex settings across the world. As part of this work stream, we have also contributed to building social science research capacity in the global south.
Publications
Awards
UKRI Global Challenge Research Fund grant (£7M) to build research capacity and capability across Middle East and North Africa
NIHR grant (£4M) to strengthen systems and services in NW and NE Syria
Welcome Trust and Medical Research grants (£1M+) to develop low-cost virtual reality to support surgery capacity in LMIC
Global Alliance for Chronic Disease grant (£2M) to support implementation of affordable, equitable and integrated multi-cancer early detection package in India
Welcome Trust (£1M+) Artificial Intelligence to Automate Radiotherapy to Treat Advanced Cancers
Welcome Trust (£1M+) Grid oncology: remaking cancer care in India
ISSF (£1M) African Prostate Cancer Disparities in Outcomes
STFC (£1M) Cloud-Based Electronic Platforms in Support of Complex Radiotherapy Planning and Research Capacity
Activities
eCancer
GOG partners closely with eCancer, a free to publish and free to access multi-media platform, that is both a publisher and a developer of free educational content with a specific focus on global cancer in LMIC. Through eCancer we create free content including briefings on topical global cancer issues, new educational content, and intelligence resources for example on COVID-19 and Cancer. We also work with eCancer to bring global webinars on ‘hot topics’ and virtual conference proceedings from all the major global meetings including eCancer patient and Spanish portals for Latin American faculty.
Journal of Cancer Policy
The Journal of Cancer Policy is GOG’s own brand cancer policy journal. Launched in 2015 it has provided a platform for a wide range of research, commentaries, and major series reflecting the plurality and depth of global oncology. The Journal of Cancer Policy is an international journal that publishes research and reviews on global cancer policy. The journal encompasses all aspects of cancer policy from prevention and public health through all modalities of control and cure, palliative care, and survivorship. It provides a platform for policy research and discussion around the world from New Zealand to Niger.
London Global Cancer Week
As founding members of UK Global Cancer Research Network the Global Oncology Group and Institute of Cancer Policy are hosting two major sessions at LGCW from 14 to 19 November. On 15th November join us for an examination of cancer care – the balance of costs with the Royal Society of Medicine and on 17th November we will co-host with The Lancet an update on the Women and Cancer Commission
Lancet Commission on Diagnostics
The ICP joined an international group of experts to examine the state of Global Diagnostics and provide recommendations to improve the support of this critical area as part of Universal Health Coverage.
Conferences
Faculty from GOG will be involved in the following global cancer meetings. Come and join us!
AORTIC
The Global Oncology Group through the Institute of Cancer Policy is an active member of the African Organization for Research and Training In Cancer (AORTIC). In addition to GOG research capacity building projects across SSA from virtual reality surgical simulation to palliative care, the GOG believes in investing in African partners, contributing to their organizational financial models towards operational independence and sustainability of their own efforts to build research and policy capacity and capability.
Supporting Ukrainian Cancer Care
The Russian invasion of Ukraine has created a profound cancer (and NCD) humanitarian crisis. The Global Oncology Group is providing critical health intelligence for cancer and palliative care during this crisis through the creation of a health security intelligence group. This group brings together global cancer experience from the Global Oncology Group at the Institute of Cancer Policy and the Cicely Saunders Institute for Palliative Care. Professor Richard Sullivan is a member of the WHO Cancer Emergency Committee and co-chairs the European Cancer Organisation and American Society of Clinical Oncology Ukrainian network. The King’s group is also assisting with estimates and analysis on the pathways Ukrainian cancer patients are taking through Europe and the capacity/capability of cancer centres in host countries to manage what has been a rapidly increasing additional burden. Much of the insight we are bringing to this crisis has been drawn from our work with colleagues in Lebanon, Turkey, Jordan and Palestine over the last five years on the Research for Health in Conflict program looking at cancer care within the Syrian conflict and during the war in Afghanistan.
Building performance metrics for the City Cancer Challenge Foundation
With most of the urban growth expected to take place in Low- and Middle-Income Countries (LMICs), cities are uniquely positioned to build resilient cancer health systems from the ground up. The City Cancer Challenge Foundation model leverages the entrepreneurship and leadership of cities to co-create new ways of working to drive equitable access to quality cancer management services. Institute of Cancer Policy, Global Oncology Group is proud to be working with the Foundation to develop an evidenced-based, three-tiered set of long-term performance indicators which, when implemented, support cancer centres in establishing a critical path of data collection to underpin monitoring and evaluation of cancer treatment and palliative care in a longitudinal manner and a key step towards incremental improvement of services and sustainability. This work will be implemented with the support of expert discussions groups drawn for the Global Oncology Group. We anticipate delivery of phase 1 reports to the City Cancer Challenge Foundation in May, with follow up work to consolidate recommendations for cancer centres in LMICs by October 2022.
News
Global analysis of cancer research papers reveals consistent sex imbalance
New research analysing female authorship of cancer research papers over a 10 year period has found a consistent sex imbalance, despite a modest increase in...
Multi-billion productivity cost of head and neck cancer revealed
New research describes a $5.6 billion (USD) loss of productivity from head and neck cancer in India during 2022, emblematic of its rising economic impact...
King's helps build cancer partnerships across Sub-Saharan Africa
The Global Oncology Group played a major role at this year’s African Organisation for Research and Training in Cancer (AORTIC) in promoting partnerships and...
Leading cancer doctors raise the alarm about “serious missteps” on cancer policy
The loss of a dedicated National Cancer Control Plan in England and Wales has been a “major misstep” at a time when the NHS is facing massive workforce...
2023 Surgery Commission offers solutions to improve cancer surgery outcomes
King’s academics have collaborated with researchers, doctors and surgeons to make eight recommendations to help improve cancer surgery outcomes across the...
ICP Board
- Mark Lawler, Belfast, Northern Ireland
- Omar Shamieh, King Hussein Cancer Centre, Jordan
- Tezer Kutluk, Hacettepe University Hospital, Turkey
- Enrique Soto Pérez de Celis, University of Colorado Cancer Centre, USA
- Karla Ungar, National Cancer Institute, Mexico
- Ishu Kataria, RTI, USA and India
- Chris Booth, Queen’s University, Canada
- Kathleen Schmeler, MD Anderson, USA
- Peter Kingham, Memorial Sloan Kettering, USA
- CS Pramesh, Tata Memorial Centre, Mumbai, India
- Gevorg Tamamyan, Yerevan State Medical University, Armenia
- Miriam Mutebi, Aga Khan University, Nairobi, Kenya
- Partha Basu, WHO International Agency for Research on Cancer
- Nirmala Bhoo-Pathy, University of Malaysia
- Yolande Lievens, University of Ghent
Our Partners
National Institute for Health Research (NIHR)
UK Research and Innovation (UKRI)
UK Global Cancer Research Network (UKGCRN)
eCancer
European Cancer Organisation (ECCO)
World Health Organisation (WHO)
National Cancer Grid of India (NCG)
Journal Cancer Policy (JCP)
Union of Medical Care and Relief Organizations (UOSSM)
City Cancer Challenge
Group leads
Related departments
- Faculty of Life Sciences & Medicine
- School of Cancer & Pharmaceutical Sciences
- Comprehensive Cancer Centre
- School of Basic & Medical Biosciences
- School of Security Studies
- Faculty of Social Science & Public Policy
- School of Global Affairs
- King’s Global Health Institute
- Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care
- Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation